HbA 1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study.
Brenda W C BongaertsOliver KußFabrice BonnetHungta ChenAndrew CooperPeter FeniciMarília Brito GomesNiklas HammarLi-Nong JiKamlesh Khunti F MedSciJesus MedinaAntonio NicolucciMarina V ShestakovaHirotaka WatadaWolfgang RathmannPublished in: Diabetes, obesity & metabolism (2023)
Most people receiving second-line glucose-lowering treatment in this global cohort achieved stable good or highly improved long-term glycaemic control. One-fifth of participants showed moderate or poor glycaemic control during follow-up. Further large-scale studies are required to characterize possible factors associated with patterns of glycaemic control to inform personalized diabetes treatment. This article is protected by copyright. All rights reserved.